New Launch23 Jan 2025, 02:32 am
Piramal Critical Care Launches Chlorpromazine Hydrochloride for Injection, USP in U.S.
AI Summary
Piramal Critical Care (PCC), a division of Piramal Pharma Limited, has announced the U.S. launch of Chlorpromazine Hydrochloride for Injection, USP. This launch marks another step in PCC's expansion of its generic injectables portfolio, which already includes a wide range of critical care products.
Key Highlights
- Piramal Critical Care launches Chlorpromazine Hydrochloride for Injection, USP in 25mg/1mL and 50mg/2 mL vials.
- This launch is the latest in a series of recent product launches from Piramal Critical Care in the generic injectables market.
- PCC launched the first to market generic of Edaravone IV Infusion in 2024 and 2023 launches of Pantoprazole Sodium for Injection, USP and Doxycycline for Injection, USP.
- Piramal Critical Care maintains a wide global footprint, delivering continuous supply to hospitals in more than 100 countries around the world.
- Piramal Critical Care has strong manufacturing and process development capabilities with state-of-the-art manufacturing facilities in Bethlehem, Pennsylvania, Digwal, India, and Dahej, India.